Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2025)
Sutro Biopharma (STRO) reported Return on Capital Employed of 135.81% for Q4 2025, down 5290.0% on a YoY basis from 2.62% in Q4 2024, and down 20.1% sequentially from 113.08% in Q3 2025.
Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2025) Analysis & Trends
Sutro Biopharma (STRO) has 8 years of Return on Capital Employed data on file, last reported at 135.81% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 5290.0% year-over-year to 135.81%; the trailing twelve-month figure through Dec 2025 stood at 135.81% (down 5290.0% YoY), and the FY2025 full-year result was 77.11%, up 316.0% from the prior year.
- Return on Capital Employed retreated to 135.81% in Q4 2025, from 113.08% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 19.3% in Q2 2021 to a low of 135.81% in Q4 2025.
- A 5-year average of 52.75% and a median of 39.61% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 2900 bps in 2021 and plunged 8417 bps in 2025, its largest moves.
- Tracing STRO's Return on Capital Employed over 5 years: stood at 31.31% in 2021, then dropped by 22 bps to 38.23% in 2022, then soared by 35 bps to 24.97% in 2023, then slumped by 232 bps to 82.9% in 2024, then tumbled by 64 bps to 135.81% in 2025.
- Business Quant data shows STRO's Return on Capital Employed at 135.81% in Q4 2025, 113.08% in Q3 2025, and 94.21% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Sutro Biopharma | 202.59 Mn | 61.16 Mn | - | -135.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.81% |
| Sep 30, 2025 | -113.08% |
| Jun 30, 2025 | -94.21% |
| Mar 31, 2025 | -113.15% |
| Dec 31, 2024 | -82.90% |
| Sep 30, 2024 | -38.34% |
| Jun 30, 2024 | -33.56% |
| Mar 31, 2024 | -28.98% |
| Dec 31, 2023 | -24.97% |
| Sep 30, 2023 | -48.48% |
| Jun 30, 2023 | -46.13% |
| Mar 31, 2023 | -40.88% |
| Dec 31, 2022 | -38.23% |
| Sep 30, 2022 | -34.27% |
| Jun 30, 2022 | -42.73% |
| Mar 31, 2022 | -41.81% |
| Dec 31, 2021 | -31.31% |
| Sep 30, 2021 | -26.75% |
| Jun 30, 2021 | -19.30% |
| Mar 31, 2021 | -20.04% |